SELLAS Life Sciences Group (NASDAQ:SLS) Posts Earnings Results, Misses Expectations By $0.01 EPS

Posted by Brian Himes on Aug 11th, 2026

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), FiscalAI reports.

SELLAS Life Sciences Group Trading Up 0.1%

Shares of SLS traded up $0.01 on Tuesday, reaching $11.05. 4,599,649 shares of the company’s stock traded hands, compared to its average volume of 8,288,508. The stock has a market cap of $2.17 billion, a PE ratio of -48.04 and a beta of 2.48. The stock’s 50 day simple moving average is $10.95 and its two-hundred day simple moving average is $7.19. SELLAS Life Sciences Group has a 52-week low of $1.39 and a 52-week high of $15.88.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Equitable Holdings Inc. raised its stake in shares of SELLAS Life Sciences Group by 18.5% during the 4th quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock worth $121,000 after purchasing an additional 5,000 shares during the period. Invesco Ltd. purchased a new position in shares of SELLAS Life Sciences Group in the 2nd quarter worth about $110,000. New York State Common Retirement Fund bought a new position in SELLAS Life Sciences Group during the second quarter valued at about $108,000. Blair William & Co. IL raised its position in SELLAS Life Sciences Group by 62.5% in the fourth quarter. Blair William & Co. IL now owns 26,002 shares of the company’s stock worth $98,000 after acquiring an additional 10,000 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in SELLAS Life Sciences Group in the second quarter valued at about $76,000. Institutional investors own 17.38% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on SLS shares. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Stock Report on SLS

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.